Ovid Therapeutics (OVID) Short Interest Ratio & Short Volume → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free OVID Stock Alerts $3.28 -0.04 (-1.21%) (As of 05/16/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Ovid Therapeutics Short Interest DataCurrent Short Volume2,820,000 sharesPrevious Short Volume2,800,000 sharesChange Vs. Previous Month+0.71%Dollar Volume Sold Short$8.60 millionShort Interest Ratio / Days to Cover13.7Last Record DateApril 30, 2024Outstanding Shares70,810,000 sharesFloat Size58,640,000 sharesShort Percent of Float4.81%Today's Trading Volume105,233 sharesAverage Trading Volume183,529 sharesToday's Volume Vs. Average57% Short Selling Ovid Therapeutics ? Sign up to receive the latest short interest report for Ovid Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatOVID Short Interest Over TimeOVID Days to Cover Over TimeOVID Percentage of Float Shorted Over Time Ad Weiss RatingsThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”Learn more about it by watching THIS NOW. Ovid Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20242,820,000 shares $8.60 million +0.7%4.8%13.7 $3.05 4/15/20242,800,000 shares $8.96 million No Change4.8%13.4 $3.20 3/31/20242,800,000 shares $8.54 million -23.7%4.8%13.7 $3.05 3/15/20243,670,000 shares $9.98 million +0.6%6.3%17.4 $2.72 2/29/20243,650,000 shares $12.41 million +1.4%6.2%22.9 $3.40 2/15/20243,600,000 shares $13.10 million +7.8%6.1%23.9 $3.64 Get the Latest News and Ratings for OVID and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20243,340,000 shares $12.93 million +8.4%5.6%23.5 $3.87 1/15/20243,080,000 shares $9.64 million +6.2%5.2%21.9 $3.13 12/31/20232,900,000 shares $9.34 million +16.9%4.9%21.3 $3.22 12/15/20232,480,000 shares $8.53 million +7.8%4.2%18.2 $3.44 11/30/20232,300,000 shares $6.84 million +7.5%3.9%19.2 $2.98 11/15/20232,140,000 shares $7.19 million +6.5%3.7%18 $3.36 10/31/20232,010,000 shares $7.14 million +2.6%3.5%13.2 $3.55 10/15/20231,960,000 shares $7.19 million -5.3%3.4%12.3 $3.67 9/30/20232,070,000 shares $7.95 million +2.0%3.6%13.4 $3.84 9/15/20232,030,000 shares $8.06 million -2.4%3.5%11.9 $3.97 8/31/20232,080,000 shares $7.00 million +12.4%3.6%6.6 $3.37 8/15/20231,850,000 shares $6.64 million +1.1%3.2%5.9 $3.59 7/31/20231,830,000 shares $6.57 million -0.5%3.1%6.3 $3.59 7/15/20231,840,000 shares $6.24 million No Change3.3%6.4 $3.39 6/30/20231,840,000 shares $6.04 million +216.7%3.3%6.4 $3.28 6/15/2023581,000 shares $2.08 million +40.2%1.0%2.2 $3.58 5/31/2023414,500 shares $1.47 million +28.7%0.7%3.3 $3.54 5/15/2023322,100 shares $1.12 million +62.3%0.6%3.2 $3.49 4/30/2023198,500 shares $710,630.00 -7.2%0.4%2.2 $3.58 4/15/2023213,900 shares $663,090.00 +2.6%0.4%2.9 $3.10 3/31/2023208,500 shares $537,930.00 -9.8%0.4%3 $2.58 3/15/2023231,200 shares $483,208.00 -5.5%0.4%3.3 $2.09 2/28/2023244,600 shares $604,162.00 +9.1%0.4%2.7 $2.47 2/15/2023224,300 shares $567,479.00 -1.1%0.4%2.6 $2.53 1/31/2023226,700 shares $566,750.00 +3.1%0.4%2.6 $2.50 1/15/2023219,800 shares $523,124.00 +2.9%0.4%2.5 $2.38 12/30/2022213,600 shares $397,296.00 -24.7%0.4%1.8 $1.86 12/15/2022283,500 shares $510,300.00 +4.5%0.5%2.4 $1.80 11/30/2022271,200 shares $480,024.00 -5.8%0.5%2.6 $1.77 11/15/2022287,800 shares $483,504.00 +3.6%0.5%2.8 $1.68 10/31/2022277,700 shares $452,651.00 -3.7%0.5%2.6 $1.63 10/15/2022288,300 shares $449,748.00 +1.8%0.5%2.6 $1.56 9/30/2022283,100 shares $520,904.00 +1.9%0.5%3.1 $1.84 9/15/2022277,800 shares $608,382.00 -3.5%0.5%2.7 $2.19Obama’s Forever Term [exposed] (Ad)America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.Start streaming it now at no cost here OVID Short Interest - Frequently Asked Questions What is Ovid Therapeutics' current short interest? Short interest is the volume of Ovid Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 2,820,000 shares of OVID short. 4.81% of Ovid Therapeutics' shares are currently sold short. Learn More on Ovid Therapeutics' current short interest. What is a good short interest ratio for Ovid Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. OVID shares currently have a short interest ratio of 14.0. Learn More on Ovid Therapeutics's short interest ratio. What is a good short interest percentage for Ovid Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.81% of Ovid Therapeutics' floating shares are currently sold short. Is Ovid Therapeutics' short interest increasing or decreasing? Ovid Therapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 2,820,000 shares, an increase of 0.7% from the previous total of 2,800,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Ovid Therapeutics' float size? Ovid Therapeutics currently has issued a total of 70,810,000 shares. Some of Ovid Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Ovid Therapeutics currently has a public float of 58,640,000 shares. How does Ovid Therapeutics' short interest compare to its competitors? 4.81% of Ovid Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Ovid Therapeutics: Eliem Therapeutics, Inc. (0.31%), Generation Bio Co. (3.61%), Merrimack Pharmaceuticals, Inc. (5.80%), Puma Biotechnology, Inc. (8.96%), uniQure (6.72%), Foghorn Therapeutics Inc. (7.05%), Veru Inc. (8.35%), G1 Therapeutics, Inc. (5.41%), 2seventy bio, Inc. (14.59%), Werewolf Therapeutics, Inc. (1.39%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Ovid Therapeutics stock? Short selling OVID is an investing strategy that aims to generate trading profit from Ovid Therapeutics as its price is falling. OVID shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Ovid Therapeutics? A short squeeze for Ovid Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of OVID, which in turn drives the price of the stock up even further. How often is Ovid Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OVID, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: ELYM Short Squeeze GBIO Short Squeeze MACK Short Squeeze PBYI Short Squeeze QURE Short Squeeze FHTX Short Squeeze VERU Short Squeeze GTHX Short Squeeze TSVT Short Squeeze HOWL Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:OVID) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the Markets348 million Americans lives to END as we know it?The Oxford ClubGold Set to EXPLODE!Gold Safe Exchange[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsHow Biden has already won 2024Porter & CompanyA once-in-a-century investment opportunityStansberry ResearchCharles Payne Demystifies OptionsUnstoppable Prosperity